Onychomycosis

Zylö Receives $600,000 NIH Phase I Grant to Develop a Novel Therapeutic to Treat Onychomycosis (Nail Fungus)

Retrieved on: 
Friday, August 19, 2022
Department of Medicine – University of Pamplona, Risk, Onychomycosis, NIH, GLOBE, Drug resistance, Toxicity, Microbiology, Clemson University, Erectile dysfunction, National Institute, Infection, Pain, National Institute of Allergy and Infectious Diseases, Quality of life, Therapy, Twitter, Program, Acne, Atomic mass, Atopic dermatitis, Wound healing, Hepatotoxicity, SBIR, Albert Einstein College of Medicine, Medicine, Nitric oxide, Pharmaceutical industry, Management

GREENVILLE, SC, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., developer of the Z-pod® topical delivery platform, has been awarded a two-year $600,000 Small Business Innovation Research (SBIR) grant to generate a final formulation of Zylö’s proprietary nitric oxide-releasing topical drug candidate optimized for the treatment of onychomycosis. The grant is sponsored by the National Institute of Allergy and Infectious Diseases, a division of the NIH.

Key Points: 
  • The grant is sponsored by the National Institute of Allergy and Infectious Diseases, a division of the NIH.
  • Onychomycosis is an extremely common and difficult-to-treat fungal nail infection that causes nail disfigurement, pain, associated infections, and psychosocial effects that negatively impact quality of life.
  • Our novel nitric oxide-releasing product promises to increase nail penetration, thereby enhancing efficacy, but without the side effects typically experienced with systemic drugs.
  • Notably, the Z-pod technology can also be adapted to provide sustained topical delivery of nitric oxide for multiple therapeutic indications.

Cipher Pharmaceuticals Reports Second Quarter 2022 Financial Results

Retrieved on: 
Thursday, August 11, 2022
Telephone, Psoriasis, Degenerative disease, TSX, Adjustment, Plasma protein binding, Marketing, Sun, EBITDA, CDN, Food, SEDAR, Industry, Management, American, Partnership, Tax, Safety, Eflornithine, Privacy, Webcast, Rheumatoid arthritis, Regulation of tobacco by the U.S. Food and Drug Administration, Intellectual property, Interim, Substance-related disorder, Growth, Hospital, Compliance, European, Income, Moberg, COVID-19, Acquisition, IFRS, Coronavirus, Tirofiban, Goal, Mission statement, Onychomycosis, FDA, Hope, Conversation, Company, Depreciation, Risk, Financial statement, Insurance, CPH, III, Adoption, Weapon, Cryptocurrency, Pharmaceutical industry, Fossil fuel, Online gambling, Mobile phone, Bookkeeping, MISSISSAUGA, Isotretinoin, IQVIA, Isotretinoin

(All figures are in U.S. dollars)

Key Points: 
  • (All figures are in U.S. dollars)
    Strong balance sheet with $24.2 million in cash at June 30, 2022
    MISSISSAUGA, ON, Aug. 11, 2022 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced its financial and operating results for the three and six month periods endedJune 30, 2022.
  • Craig Mull, Interim CEO commented,"We are pleased to report that Cipher delivered another strong quarter, generating positive net income and cash from operating activities.
  • Cipher will hold a conference call onAugust 12, 2022, at8:30 a.m. (ET)to discuss its financial results and other corporate developments.
  • Cipher Pharmaceuticals (TSX: CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products.

DermBiont Announces Positive Phase 2 Clinical Trial Data Treating Seborrheic Keratosis with SM-020, the First and Only Targeted Topical Treatment for these Common Benign Tumors

Retrieved on: 
Thursday, June 23, 2022
Biotechnology, FDA, Men, Health, Family, Consumer, Other Health, Pharmaceutical, Other Science, Research, Teens, Science, Women, Clinical Trials, Skin, SK, Therapy, AKT, Dermatology, Itch, CEO, SKS, Entrepreneurship, Erythema, Pain, Atopic dermatitis, Clinical trial, Human, Intention, Onychomycosis, Edema, PLA, Dermatophytosis, Patient, Face, Neoplasm, Pharmaceutical industry, Medical imaging, Wood-plastic composite, Medical device

SKs are benign clonal tumors of the skin that often appear over the age of thirty-five.

Key Points: 
  • SKs are benign clonal tumors of the skin that often appear over the age of thirty-five.
  • All three cohorts saw improvement and clearance of SKs, with the effect being most pronounced in the two 28-day treatment cohorts.
  • DermBiont plans to initiate a 100+ patient Phase 2 trial in early 2023, and Phase 3 trials could be initiated as early as Q1 2024.
  • DermBionts mission is to become the worlds leading precision dermatology company developing and commercializing targeted topical therapeutics that treat, cure, and prevent diseases.

Seth M. Birnbaum Joins Pharma Company Hallux Inc. Board of Directors

Retrieved on: 
Wednesday, May 18, 2022
Economics, HSG, Risk management, Infection, Patient, Bridgewater Associates, Amherst College, BA, Open Doors, Institutional investor, Philosophy, Onychomycosis, Safety, Seth Lederman, CFA, Pharmaceutical industry, Management, Toe

LAGUNA HILLS, Calif., May 18, 2022 /PRNewswire-PRWeb/ -- Hallux Inc, a clinical stage pharmaceutical company, announced today that following last month's initial closing of its $9.4 million Series A-2 financing round, veteran Bridgewater Associates Partner Seth M. Birnbaum has been appointed to its board of directors. Proceeds of the capital raise will be used to further fund the company's phase 2 clinical program evaluating Hallux Subungual Gel (HSG) for the treatment of onychomycosis (toenail fungus).

Key Points: 
  • LAGUNA HILLS, Calif., May 18, 2022 /PRNewswire-PRWeb/ -- Hallux Inc, a clinical stage pharmaceutical company, announced today that following last month's initial closing of its $9.4 million Series A-2 financing round, veteran Bridgewater Associates Partner Seth M. Birnbaum has been appointed to its board of directors.
  • Hallux CEO Mark Taylor said, "On behalf of our entire board, we are excited to have Seth join Hallux as a director.
  • Our board members are both personally invested in Hallux and extremely experienced in clinical development, specifically onychomycosis.
  • Seth M. Birnbaum, CFA is a 20-year veteran of Bridgewater Associates , where he is a partner and senior member of the investment team.

Cipher Pharmaceuticals Reports Strong First Quarter 2022 Financial Results

Retrieved on: 
Thursday, May 12, 2022
CPH, Telephone, Company, Eflornithine, Conversation, Mission statement, EBITDA, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Depreciation, Webcast, Sun Pharma, Moberg, Goal, Insurance, SEDAR, Tax, Coronavirus, Risk, March 31, Privacy, COVID-19, Marketing, Adjustment, TSX, Tirofiban, FDA, Hope, Industry, Sun, Substance-related disorder, Partnership, Intellectual property, Compliance, Hospital, Management, Financial statement, Onychomycosis, IFRS, Adoption, Acquisition, Growth, Interim, Degenerative disease, Weapon, Online gambling, Pharmaceutical industry, Fine chemical, Renewable energy, Mobile phone, Bookkeeping, Isotretinoin, MISSISSAUGA, IQVIA, Isotretinoin

Our strong results have been driven by our reduced cost structure in addition to improved distribution and supply agreements."

Key Points: 
  • Our strong results have been driven by our reduced cost structure in addition to improved distribution and supply agreements."
  • During the first quarter, Cipher announced an extension of the distribution and supply agreement with Sun Pharmaceutical Industries ("Sun Pharma") through December 31, 2026.
  • This extension will provide Cipher with an additional four years of visibility into stable revenue and cashflow on the isotretinoin portfolio.
  • Cipher will hold a conference call onMay 13, 2022, at8:30 a.m. (ET)to discuss its financial results and other corporate developments.

Cipher Pharmaceuticals Announces Partner, Moberg Pharma's Regulatory Submission to FDA for North American Phase 3 Study

Retrieved on: 
Tuesday, March 22, 2022
Adoption, Market capitalization, Company, Interim, Moberg, OMX, Marketing, Terbinafine, Substance-related disorder, Coronavirus, Compliance, Risk, Hospital, CDN, Privacy, Food, Onychomycosis, TSX, Nasdaq Stockholm, Industry, Goal, Hope, COVID-19, Regulation of tobacco by the U.S. Food and Drug Administration, Intellectual property, CRO, CPH, FDA, Insurance, Acquisition, Patient, Partnership, Pharmaceutical industry, Fine chemical, IQVIA

The randomized, multicenter, vehicle-controlled Phase 3 study will include approximately 350 patients in North America.

Key Points: 
  • The randomized, multicenter, vehicle-controlled Phase 3 study will include approximately 350 patients in North America.
  • The study design builds on the experience gained from the previous Phase 3 studies.
  • Moberg Pharma will cooperate with the same CRO, lead investigator and successful sites from the previous North American study.
  • "We are pleased to see the continued progress that Moberg is making to commercialize MOB-015," said Craig Mull, Interim CEO of Cipher.

Almirall's Full-Year 2021 Results : Almirall delivers high end of the 2021 upgraded guidance with solid performance from growth drivers

Retrieved on: 
Monday, February 21, 2022
OAB, Prescription, ALM, H1, Cytokine, TCS, OTC, Onychomycosis, Core, Acne, IND, AD, Scalp, Dermatology, Adolescence, Board, European Medicines Agency, Growth, Atopic dermatitis, Safety, Disease, AK, Acceleration, Veni, vidi, vici, General officer, Adherence, Quality of life, Face, AstraZeneca, Population, Week, Water, Tildrakizumab, Advocate, Tetracycline, Sleep, EMA, World Health Organization, Patient, Technology, Science, Income, TRX, Itch, Psoriasis, Annual, Sales, Ageing, MM, Adult, Ciclosporin, Traction, Almirall, AGM, Smith W. Brookhart, EBITDA, Renewable energy, Fine chemical, Rope, Pharmaceutical industry, Vaccine, Holding company, Sarecycline, EU, European, Skin, Tirbanibulin

Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, has announced its full-year 2021 financial results today.

Key Points: 
  • Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, has announced its full-year 2021 financial results today.
  • Net Salesof 827.2 MM represent a 2.5% year-on-year growth, driven by positive contribution from growth drivers and a strong EU dermatology performance.
  • Core EBITDA*was 211.3 MM, a growth of 16.7%, boosted by strong performance of the growth drivers.
  • Almirall achieved solid operating results, delivering on the upgraded 2021 guidance, as the core business continued to perform well in line with expectations.

Almirall's Full-Year 2021 Results : Almirall delivers high end of the 2021 upgraded guidance with solid performance from growth drivers

Retrieved on: 
Monday, February 21, 2022
OAB, Prescription, ALM, H1, Cytokine, TCS, OTC, Onychomycosis, Core, Acne, IND, AD, Scalp, Dermatology, Adolescence, Board, European Medicines Agency, Growth, Atopic dermatitis, Safety, Disease, AK, Acceleration, Veni, vidi, vici, General officer, Adherence, Quality of life, Face, AstraZeneca, Population, Week, Water, Tildrakizumab, Advocate, Tetracycline, Sleep, EMA, World Health Organization, Patient, Technology, Science, Income, TRX, Itch, Psoriasis, Annual, Sales, Ageing, MM, Adult, Ciclosporin, Traction, Almirall, AGM, Smith W. Brookhart, EBITDA, Renewable energy, Fine chemical, Rope, Pharmaceutical industry, Vaccine, Holding company, Sarecycline, EU, European, Skin, Tirbanibulin

Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, has announced its full-year 2021 financial results today.

Key Points: 
  • Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, has announced its full-year 2021 financial results today.
  • Net Salesof 827.2 MM represent a 2.5% year-on-year growth, driven by positive contribution from growth drivers and a strong EU dermatology performance.
  • Core EBITDA*was 211.3 MM, a growth of 16.7%, boosted by strong performance of the growth drivers.
  • Almirall achieved solid operating results, delivering on the upgraded 2021 guidance, as the core business continued to perform well in line with expectations.

APMA Grants Seal of Approval for JUBLIA® (efinaconazole) Topical Solution, 10%

Retrieved on: 
Monday, December 6, 2021
Canadian Securities Administrators, Degenerative disease, NYSE, Onychomycosis, Podiatry, Physician, Stinger, Global health, DPM, LinkedIn, Blister, American Podiatric Medical Association, Skin care, APMA, CEO, Mouth, Dermatology, Ankle, Foot, Atopic dermatitis, Fear, Mycosis, Quality control, Gastroenterology, Swelling, Irritation, News, Review, Nail, Distortion, Vagina, Education, Bausch Health, U.S. Securities and Exchange Commission, Twitter, DPMS, FDA, Acne, Form 10-K, Itch, Patient, Skin, Red, Safety, Psoriasis, Leg, Selected Patient Information Resources in Asian Languages, BHC, Program, Annual report, COVID-19, Pain, Agent handling, Fungus, Pharmaceutical industry, Dietary supplement, Birth control, Petroleum jelly, Petrochemical

"The APMA Seal of Approval recognizes the demonstrated safety and efficacy profile of JUBLIA and its continued use as a valuable treatment option for adults and children with toenail fungal infections.

Key Points: 
  • "The APMA Seal of Approval recognizes the demonstrated safety and efficacy profile of JUBLIA and its continued use as a valuable treatment option for adults and children with toenail fungal infections.
  • To earn the APMA Seal of Approval, products must undergo a rigorous scientific review by a committee of APMA podiatrists.
  • "APMA is proud to bestow its Seal of Approval on products such as JUBLIA that meet our physicians' highest standards for safety and effectiveness."
  • Important Safety Information for JUBLIA(efinaconazole) Topical Solution, 10%
    JUBLIA (efinaconazole) Topical Solution, 10% is a prescription medicine used to treat fungal infections of the toenails.

Cosmopolitan Selects Aerolase as "Best Acne Laser" in Its Holy Grail Awards, Further Building Aerolase Brand Equity

Retrieved on: 
Monday, November 29, 2021
Patient, Skin, Hair removal, Ageing, CEO, Psoriasis, Bacteria, Exocrine gland, MD, MT, Inflammation, Prescription, EXCLAIM, Solution, Acne, Rosacea, Female, Melasma, Adult, Wound healing, Hospital, Associate, Multimedia, Today (American TV program), RealSelf, Onychomycosis, Pharmaceutical industry

Based on months of comparative testing, theCosmobeauty team awarded Aerolase the best acne products and most effective acne treatment systems.

Key Points: 
  • Based on months of comparative testing, theCosmobeauty team awarded Aerolase the best acne products and most effective acne treatment systems.
  • NeoClear, the brand name of Aerolase's unique acne treatment, works to quickly clear acne at its root causes, as proven in clinical trials.
  • It reduces sebum production from the sebaceous glands, suppresses inflammation of active acne, and destroys the p. acnes bacteria on the skin, including facial acne, truncal acne, and adult female hormonal acne.
  • "Expect a chin free of cystic acne after just a few sessions," says Chloe Metzger, deputy beauty director ofCosmopolitan.